Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

The company announced the positive data for the dual glucagon-like peptide-1 receptor (GLP-1R)/gastric inhibitory polypeptide (GIP) receptor agonist at ObesityWeek 2024, taking place in Texas ...

plus a glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist, tirzepatide, in the first quarter of calendar year 2025. Furthermore, we are excited to advance our obesity ...

The two main incretins are GLP-1 and GIP or gastric inhibitory peptide. They collectively increase the release of insulin and ...

Shalini’s obesity problem Shalini*, a 61-year-old woman is at the pinnacle of her career. She immigrated from India when she ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Glucagon-like peptide-1 receptor agonists (GLP-1s for ... These are dual-acting, meaning they target two receptors in the body: gastric inhibitory polypeptide (GIP) and GLP-1.